Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,019 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 19,019 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F5: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby daughter | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby son | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | Indirectby daughter | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
F5: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Twist Bioscience Corp
Report date August 07, 2026 · Filed August 11, 2026
Section 16 reporting ended · disclosed 2026-02-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,084 |
Ending reported balance
After 2026-08-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Exercise / conversion · Acquired 18,417 · Balance 39,501 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. Row 2 · 2026-08-07 · Sale · Disposed 18,417 · Balance 21,084 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2028-09-13 | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-07 · Exercise / conversion · Disposed 18,417 · Balance 0 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy the Chess 1997 Trust | 42,528 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 42,528 F2: The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026.
F2: The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.
F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2020 Filed Feb 7, 2020 02:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 1,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-001013 · marketforms-47695.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,234 F1 · shares: Represents a restricted stock unit award (the "RSU Award") of which 100% vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2020 Filed Mar 5, 2021 21:40 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 11,297 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001214659-21-002795 · marketforms-51437.xml · derivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,297 Underlying: Common Stock · 11,297 shares Expires 2030-02-03 F1 · shares: The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. F1 · derivative.underlying_shares: The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. F1 · balance_after: The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 23:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,000 | $17.99 | $71,960.00 |
DisclosureSEC source: 0001209191-19-051405 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.73 to $18.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 13,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-19-051042 · doc4.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-09-24 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2019. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051042 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,973 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 25, 2019. Read SEC document |
| July 23, 2019 Filed Oct 9, 2019 20:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 5,590 | $0.00 Strike: $30.41 | $0.00 |
DisclosureSEC source: 0001209191-19-052818 · doc4.xml · derivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,590 Underlying: Common Stock · 5,590 shares Expires 2029-07-22 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 23, 2019 Filed Mar 5, 2021 21:30 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 10,588 | $0.00 Strike: $30.41 | $0.00 |
DisclosureSEC source: 0001214659-21-002783 · marketforms-51612.xml · derivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,588 Underlying: Common Stock · 10,588 shares Expires 2029-07-22 F1 · shares: The Form 4 originally filed on October 9,2019 incorrectly reported 5,590 options. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. F1 · derivative.underlying_shares: The Form 4 originally filed on October 9,2019 incorrectly reported 5,590 options. F1 · balance_after: The Form 4 originally filed on October 9,2019 incorrectly reported 5,590 options. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:21 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052908 · doc4.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:21 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052908 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,473 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 23:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,500 | $56.81 | $255,645.00 |
DisclosureSEC source: 0001209191-18-051999 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,723 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $55.71 to $58.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-18-036516 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,000 | $55.16 | $551,600.00 |
DisclosureSEC source: 0001209191-18-036516 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,223 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $52.97 to $56.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 10,000 | $14.26 | $142,600.00 |
DisclosureSEC source: 0001209191-18-036516 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-18-028189 · doc4.xml · derivative · entry 6 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-18-028189 · doc4.xml · derivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,000 | $82.81 | $1,242,150.00 |
DisclosureSEC source: 0001209191-18-028189 · doc4.xml · nonDerivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,223 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.47 to $85.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $5.14 | $77,100.00 |
DisclosureSEC source: 0001209191-18-028189 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,000 | $82.79 | $827,900.00 |
DisclosureSEC source: 0001209191-18-028189 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,223 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.47 to $85.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 10,000 | $14.26 | $142,600.00 |
DisclosureSEC source: 0001209191-18-028189 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-18-024450 · doc4.xml · derivative · entry 6 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2019-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-18-024450 · doc4.xml · derivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,000 | $92.14 | $1,382,100.00 |
DisclosureSEC source: 0001209191-18-024450 · doc4.xml · nonDerivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,223 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.19 to $94.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $5.14 | $77,100.00 |
DisclosureSEC source: 0001209191-18-024450 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,000 | $92.15 | $921,500.00 |
DisclosureSEC source: 0001209191-18-024450 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,223 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.15 to $94.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 10,000 | $14.26 | $142,600.00 |
DisclosureSEC source: 0001209191-18-024450 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 21, 2017 Filed Sep 25, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,400 | $21.72 | $139,008.00 |
DisclosureSEC source: 0001209191-17-053878 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,223 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.15 to $21.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053611 · doc4.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: common stock · 22,500 shares Expires 2025-09-18 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053611 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,623 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 19, 2017. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001209191-17-033345 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,000 | $19.79 | $98,950.00 |
DisclosureSEC source: 0001209191-17-033345 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,623 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.60 to $19.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 5,000 | $8.37 | $41,850.00 |
DisclosureSEC source: 0001209191-17-033345 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001209191-17-027576 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2017-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,000 | $18.72 | $93,600.00 |
DisclosureSEC source: 0001209191-17-027576 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,623 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.41 to $18.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 5,000 | $8.37 | $41,850.00 |
DisclosureSEC source: 0001209191-17-027576 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001209191-17-021166 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2017-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,000 | $15.41 | $77,050.00 |
DisclosureSEC source: 0001209191-17-021166 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,623 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.18 to $15.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 5,000 | $8.37 | $41,850.00 |
DisclosureSEC source: 0001209191-17-021166 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on September 14, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001209191-16-142661 · doc4.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-09-20 F4 · derivative.exercise_date: This option vests in equal monthly installments over the one-year period beginning on September 30, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142661 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,623 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 21, 2016. F3 · balance_after: This number includes 4,914 shares held by the reporting person in the Issuer's 401(k) plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c). Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142019 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F4 · derivative.exercise_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F4 · derivative.expiration_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142019 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F3 · balance_after: This number includes 4,914 shares held by the reporting person in the Issuer's 401(k) plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c). F5 · balance_after: The total holdings 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on September 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company, and vested on September 15, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 12,000 | $19.21 | $230,520.00 |
DisclosureSEC source: 0001209191-16-142019 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,623 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.97 to $19.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 4,914 shares held by the reporting person in the Issuer's 401(k) plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.